Cargando…
A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro
Vascular calcification (VC) and osteoporosis are age-related diseases and significant risk factors for the mortality of elderly. VC and osteoporosis may share common risk factors such as renin-angiotensin system (RAS)-related hypertension. In fact, inhibitors of RAS pathway, such as angiotensin type...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967071/ https://www.ncbi.nlm.nih.gov/pubmed/36838684 http://dx.doi.org/10.3390/molecules28041693 |
_version_ | 1784897173907832832 |
---|---|
author | Jeong, Seongtae Lee, Bok-Sim Jung, Seung Eun Yoon, Yoojin Song, Byeong-Wook Kim, Il-Kwon Choi, Jung-Won Kim, Sang Woo Lee, Seahyoung Lim, Soyeon |
author_facet | Jeong, Seongtae Lee, Bok-Sim Jung, Seung Eun Yoon, Yoojin Song, Byeong-Wook Kim, Il-Kwon Choi, Jung-Won Kim, Sang Woo Lee, Seahyoung Lim, Soyeon |
author_sort | Jeong, Seongtae |
collection | PubMed |
description | Vascular calcification (VC) and osteoporosis are age-related diseases and significant risk factors for the mortality of elderly. VC and osteoporosis may share common risk factors such as renin-angiotensin system (RAS)-related hypertension. In fact, inhibitors of RAS pathway, such as angiotensin type 1 receptor blockers (ARBs), improved both vascular calcification and hip fracture in elderly. However, a sex-dependent discrepancy in the responsiveness to ARB treatment in hip fracture was observed, possibly due to the estrogen deficiency in older women, suggesting that blocking the angiotensin signaling pathway may not be effective to suppress bone resorption, especially if an individual has underlying osteoclast activating conditions such as estrogen deficiency. Therefore, it has its own significance to find alternative modality for inhibiting both vascular calcification and osteoporosis by directly targeting osteoclast activation to circumvent the shortcoming of ARBs in preventing bone resorption in estrogen deficient individuals. In the present study, a natural compound library was screened to find chemical agents that are effective in preventing both calcium deposition in vascular smooth muscle cells (vSMCs) and activation of osteoclast using experimental methods such as Alizarin red staining and Tartrate-resistant acid phosphatase staining. According to our data, citreoviridin (CIT) has both an anti-VC effect and anti-osteoclastic effect in vSMCs and in Raw 264.7 cells, respectively, suggesting its potential as an effective therapeutic agent for both VC and osteoporosis. |
format | Online Article Text |
id | pubmed-9967071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99670712023-02-26 A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro Jeong, Seongtae Lee, Bok-Sim Jung, Seung Eun Yoon, Yoojin Song, Byeong-Wook Kim, Il-Kwon Choi, Jung-Won Kim, Sang Woo Lee, Seahyoung Lim, Soyeon Molecules Article Vascular calcification (VC) and osteoporosis are age-related diseases and significant risk factors for the mortality of elderly. VC and osteoporosis may share common risk factors such as renin-angiotensin system (RAS)-related hypertension. In fact, inhibitors of RAS pathway, such as angiotensin type 1 receptor blockers (ARBs), improved both vascular calcification and hip fracture in elderly. However, a sex-dependent discrepancy in the responsiveness to ARB treatment in hip fracture was observed, possibly due to the estrogen deficiency in older women, suggesting that blocking the angiotensin signaling pathway may not be effective to suppress bone resorption, especially if an individual has underlying osteoclast activating conditions such as estrogen deficiency. Therefore, it has its own significance to find alternative modality for inhibiting both vascular calcification and osteoporosis by directly targeting osteoclast activation to circumvent the shortcoming of ARBs in preventing bone resorption in estrogen deficient individuals. In the present study, a natural compound library was screened to find chemical agents that are effective in preventing both calcium deposition in vascular smooth muscle cells (vSMCs) and activation of osteoclast using experimental methods such as Alizarin red staining and Tartrate-resistant acid phosphatase staining. According to our data, citreoviridin (CIT) has both an anti-VC effect and anti-osteoclastic effect in vSMCs and in Raw 264.7 cells, respectively, suggesting its potential as an effective therapeutic agent for both VC and osteoporosis. MDPI 2023-02-10 /pmc/articles/PMC9967071/ /pubmed/36838684 http://dx.doi.org/10.3390/molecules28041693 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jeong, Seongtae Lee, Bok-Sim Jung, Seung Eun Yoon, Yoojin Song, Byeong-Wook Kim, Il-Kwon Choi, Jung-Won Kim, Sang Woo Lee, Seahyoung Lim, Soyeon A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
title | A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
title_full | A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
title_fullStr | A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
title_full_unstemmed | A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
title_short | A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
title_sort | low concentration of citreoviridin prevents both intracellular calcium deposition in vascular smooth muscle cell and osteoclast activation in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967071/ https://www.ncbi.nlm.nih.gov/pubmed/36838684 http://dx.doi.org/10.3390/molecules28041693 |
work_keys_str_mv | AT jeongseongtae alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT leeboksim alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT jungseungeun alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT yoonyoojin alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT songbyeongwook alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT kimilkwon alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT choijungwon alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT kimsangwoo alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT leeseahyoung alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT limsoyeon alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT jeongseongtae lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT leeboksim lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT jungseungeun lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT yoonyoojin lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT songbyeongwook lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT kimilkwon lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT choijungwon lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT kimsangwoo lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT leeseahyoung lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT limsoyeon lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro |